Skip to main content
Fig. 1 | BMC Health Services Research

Fig. 1

From: Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database

Fig. 1

The characteristics of ADR reports for infliximab (Remicade, Janssen Inc.) and adalimumab (Humira, AbbVie Inc.) in the CVAR database. a. The number of ADR reports in 2014–2018. b. Sex distribution of the ADR reports for infliximab and adalimumab. Females are overrepresented for both drugs. c. Age distribution of the ADR reports for infliximab and adalimumab. d. ADR outcomes. e. and f. Disease indications for Remicade and adalimumab ADR reports

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us